Editas Medicine (EDIT) shares were up almost 7% in recent trading Monday after the company said that its renizgamglogene autogedtemcel, or reni-cel, therapy continued to be well-tolerated in sickle cell disease patients.
Updated data from the company's clinical trial showed that all 28 subjects with severe sickle cell disease showed a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant, Editas said.
The company also said that 27 of the patients experienced no vaso-occlusive events, that cause pain and other complications, while some patients showed improvements in markers such as hemoglobin levels and fetal hemoglobin.
Editas said it would present the updated clinical data at the American Society of Hematology annual meeting on Monday.
Price: 2.29, Change: +0.15, Percent Change: +6.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。